Kinase inhibitors are efficient in reducing cancer cell viability in cases where malignant cells present a dependency or addiction to the targeted kinase 1 . Genetic alterations can cause constitutive activation of pro-survival and proliferative pathways and often determine the extent by which cancer cells respond to targeted drugs 2, 3 . However, other biochemical events, not directly linked to genetic mutations may also contribute to the modulation of oncogenic kinase activity and thus influence responses to kinase targeted drugs 4, 5 . Here, we integrated drug sensitivity, proteomic, phosphoproteomic, immunophenotypic and genomic analyses of primary AML to rationalize responses and identify determinants of sensitivity of AML cells to targeted compounds of clinical and preclinical interest in this disease.
We investigated the effects on cell viability of inhibitors for the kinases FLT3/PKC (midostaurin), PAK (PF-3758309), CK2 (silmitasertib), MEK (trametinib) and P38 (TAK-715). Hereafter named as FLT3/PKCi, PAKi, CK2i, MEKi, and P38i, respectively. Dose response curves for cells obtained from 36 AML patients (Data File S1) showed heterogeneous responses to all compounds ( Figure S1 ). However, samples of the M4 FAB subtype were on average more sensitive than M1 samples to MEKi (Figure 1a ).
Based on the surface expression of a set of co-expressed CD markers ( Figure S2a ), mass cytometry data subdivided our patient samples into two groups (Figure 1b (heat-map) ). These analyses could be performed in 30 cases with sufficient number of cells and produced two main groups, which we termed CDs+ and CDs-, consisting of 12 and 18 patients, respectively. Untargeted mass spectrometry proteomics Since CDs+ cases activated kinase survival pathways to a greater extent than CDs-cases, we reasoned that cells from these groups would respond differently to kinase inhibitors. Consistently with this hypothesis, cell viability analysis as a function of treatment with kinase inhibitors showed that CDs+ cases were more sensitive than CDs-to MEKi (at 10, 100 and 1,000nM), FLT3/PKCi (1 and 10μM) and PAKi (1μM) (Figure 1c ). These concentrations are physiologically relevant for MEKi and FLT3/PKCi 8, 9 .
Together, our results suggest that CDs+ cells had higher expression of proteins associated with myelomonocytic differentiation and kinase-signaling relative to negative cells, and consequently showed high phosphorylation and activation of pro-survival kinases, which was translated into an increased sensitivity to treatments with PAKi, midostaurin and trametinib.
In order to rationalize drug responses with greater detail, we sequenced 25 genes frequently mutated in AML in 27 cases of our cohort (Data File S4, sequencing failed in 3 samples). We found that genes involved in kinase-signaling (NRAS, BRAF and FLT3), were more frequently mutated in CDs+ cases Figure S4a ).
In conclusion, we found that AML cells remodel their kinase-signaling network during differentiation, resulting in a marked increase in the activity of pro-survival pathways regulated by MEK and PKC.
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